Get a real taste and understanding of the business and culture of one of the world's great research-based cellular and gene therapy discovery and development companies.
EXPLORE MORECreative Biolabs has a tradition of commitment. To achieve efficient execution and regulatory approval, we offer careful considerations of your program for the development of a cellular or gene therapy product – now and in the future.
EXPLORE MOREWe focus on unmet needs and develop novel cellular and gene drugs and solutions that offer significant benefits over existing options.
EXPLORE MORETo accelerate advanced breakthroughs of your projects, we offer broad range of platforms which enable our clients be free to tackle problems with cutting-edge technologies from different angles and in different methods.
EXPLORE MOREUse the resources in our library to help you understand your options and make critical decisions for your study. We offer oncolytic virus, CAR-T, and dendritic cell related documents, as well as newsletter. If you don’t find the answers you’re looking for, contact us for additional assistance.
EXPLORE MORE
TOSO, also known as Fas-inhibitory molecule 3 (FAIM3) or Fc mu receptor (FCMR) in humans is encoded by the FCMR gene. FCMR
was defined as a 60-kD transmembrane sialoglycoprotein and FCMR (TOSO) expression was up-regulated on B cells, but was down-modulated on T cells, suggesting differential regulation of TOSO expression during B and T cell activation. Human FCMR mRNA was strongly
expressed in hematopoietic tissues such as the spleen, thymus and peripheral blood leukocytes. Intracellular upregulation of Fc mu receptor (FCMR, FAIM3/TOSO) gene in the leukemic lymphocytes of the patients with CLL may be an important parameter in predicting the progression of the disease.
Loading...| CAT | Product Name | Target Species | Antibody Clone | Antibody Host | Receptor Construction | Vector Type | Targeting Cell Type | Inquiry & Datasheet |
| CAR-LC125 | Anti-TOSO (6B10) h(CD28-CD3ζ) CAR, pCDCAR1 | Human | 6B10 | Rat | scFv-CD28-CD3ζ | Retroviral | T cell |
Nanoparticle Tiny Tech for Programming T Cells: A novel technology to increase the efficiency and value of your CAR-T therapy project.
LEARN MORE
End-to-end CAR Hybrid TCR (CHyT)-T Cell Therapy Development Services: A novel solution to engineer T cell to be a promising cellular therapy with the complete TCR without HLA dependence.
LEARN MORE
TRAC-CAR-T Cell Development with CRISPR/Cas9 Technology: A novel technology to build more powerful CAR-T cells.
LEARN MORE
The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders
LEARN MORE
